From:
Sent: 07 October 2020 10:58
To:
Cc:

(SANTE); (SANTE); (SANTE);

(SANTE); (SANTE);

(SANTE);

**Subject:** RE: Vaccines Europe CMC document

**Attachments:** VE position on global management of PACs for COVID-19

vaccines\_final\_5 October 2020.docx; VE position on global

management of PACs for COVID-19 vaccines final 5 October 2020.pdf

Dear

We would like to thank you for your email and for sharing with us the position paper which we have transmitted to EMA.

Kind regards,

Unit "Medicines: policy, authorisation and monitoring"



## **European Commission**

DG Health and Food Safety

This message represents solely the views of its author and can not be regarded as the official position of the Commission. It is intended solely for the person to whom it is addressed and may contain confidential information. If you have received this message in error, please notify me as soon as possible.

From: @vaccineseurope.eu> Sent: Tuesday, October 6, 2020 10:00 AIVI To: (SANTE) < @ec.europa.eu>; (SANTE) @ec.europa.eu>; (SANTE) @ec.europa.eu>; (SANTE) @ec.europa.eu>; @ec.europa.eu>; (SANTE) · (SANTE) @ec.europa.eu>; SANTE PHARMACEUTICALS B5 <SANTE-</pre> PHARMACEUTICALS-B5@ec.europa.eu> Cc: @sanofi.com>; @gsk.com>; @vaccineseurope.eu> **Subject:** Vaccines Europe CMC document

Dear

I hope this email finds you well.

Further to the call of 17 September and as requested by the EMA representatives, please find attached a Vaccines Europe paper on "Global management of CMC Post- Approval Changes for COVID-19" where additional information/examples are given.

Could you please be so kind and share this paper with

Best regards,

Vaccines Europe
Rue du Trône 108, B-1050 Brussels

Tel: +32(2)626.25.55 (Switchboard)

@vaccineseurope.eu
www.vaccineseurope.eu
Transparency Register ID: 53073567234-18

